|Articles|December 8, 2014
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Author(s)Agnes Shanley
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FAQ: What You Need to Know about the Current Antibody Pipeline
3
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
4
Inside Codexis: Redefining Pharma Biocatalysis
5